Evidence map›Paper›PMID 36131240›Full record

ArticleBMC genomics2022

Predicting nicotine metabolism across ancestries using genotypes.

James W Baurley, Andrew W Bergen, Carolyn M Ervin, Sung-Shim Lani Park, Sharon E Murphy, Christopher S McMahan

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

James W BaurleyBioRealm LLC, 340 S Lemon Ave, Suite 1931, 91789, Walnut, CA, USA. baurley@biorealm.ai.
Andrew W BergenBioRealm LLC, 340 S Lemon Ave, Suite 1931, 91789, Walnut, CA, USA.
Carolyn M ErvinBioRealm LLC, 340 S Lemon Ave, Suite 1931, 91789, Walnut, CA, USA.
Sung-Shim Lani ParkUniversity of Hawaii, 701 Ilalo Street, 96813, Honolulu, HI, USA.
Sharon E MurphyUniversity of Minnesota, 2231 6th St SE, 55455, Minneapolis, MN, USA.
Christopher S McMahanClemson University, 220 Parkway Drive, 29634, Clemson, SC, USA.
BioRealm (United States) · USClemson University · USOregon Urology Institute · USUniversity of Hawaii System · USUniversity of Minnesota · US

Funding

VERY LOW NICOTINE CIGARETTES IN SMOKERS WITH SCHIZOPHRENIAU54DA031659 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DONNY, ERIC CHRISTIAN · 2011 to 2022
$64.7M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
Untargeted Adductomics to Characterize Ethnic Differences in the Exposome of SmokersP01CA138338 · NCI · UNIVERSITY OF MINNESOTA · PI DOROTHY K HATSUKAMI · 2010 to 2026
$33.4M
University of Toronto Coordinating Genetics Core & Clinical Trial SiteU01DA020830 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI LERMAN, CARYN · 2005 to 2014
$22.4M
PHARMACOKINETICS &PHARMACODYNAMICS OF NICOTINER01DA002277 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BENOWITZ, NEAL L · 1985 to 2012
$6.3M
GENES, DIET AND CARCINOGEN ACTIVATION IN SMOKERSR01CA085997 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI LE MARCHAND, LOIC · 2000 to 2004
$3.6M
Smokescreen Translational (TL) Analysis PlatformR44AA027675 · NIAAA · BIOREALM · PI BAURLEY, JAMES WILLIAM, BERGEN, ANDREW W · 2018 to 2020
$1.7M
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINER37DA002277 · NIDA · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI BENOWITZ, NEAL L · 1993 to 2002
$1.6M
PHARMACOKINETICS OF NICOTINE IN TWINSR01DA011170 · NIDA · SRI INTERNATIONAL · PI SWAN, GARY E · 1998 to 2002
$1.5M
Smokescreen Translational (TL) Analysis PlatformR43DA041211 · NIDA · BIOREALM · PI BAURLEY, JAMES WILLIAM, BERGEN, ANDREW W · 2016 to 2016
$150k
NCI NIH HHS P01 CA138338NCI NIH HHS R01 CA085997NCI NIH HHS U01 CA164973NIAAA NIH HHS R44 AA027675NIAAA NIH HHS R44AA027675NIDA NIH HHS R01 DA002277NIDA NIH HHS R01 DA011170NIDA NIH HHS R37 DA002277NIDA NIH HHS R43 DA041211NIDA NIH HHS R43DA041211NIDA NIH HHS U01 DA020830NIDA NIH HHS U54 DA031659
6 · The paper itself

Abstract

backgroundThere is a need to match characteristics of tobacco users with cessation treatments and risks of tobacco attributable diseases such as lung cancer. The rate in which the body metabolizes nicotine has proven an important predictor of these outcomes. Nicotine metabolism is primarily catalyzed by the enzyme cytochrone P450 (CYP2A6) and CYP2A6 activity can be measured as the ratio of two nicotine metabolites: trans-3'-hydroxycotinine to cotinine (NMR). Measurements of these metabolites are only possible in current tobacco users and vary by biofluid source, timing of collection, and protocols; unfortunately, this has limited their use in clinical practice. The NMR depends highly on genetic variation near CYP2A6 on chromosome 19 as well as ancestry, environmental, and other genetic factors. Thus, we aimed to develop prediction models of nicotine metabolism using genotypes and basic individual characteristics (age, gender, height, and weight).

resultsWe identified four multiethnic studies with nicotine metabolites and DNA samples. We constructed a 263 marker panel from filtering genome-wide association scans of the NMR in each study. We then applied seven machine learning techniques to train models of nicotine metabolism on the largest and most ancestrally diverse dataset (N=2239). The models were then validated using the other three studies (total N=1415). Using cross-validation, we found the correlations between the observed and predicted NMR ranged from 0.69 to 0.97 depending on the model. When predictions were averaged in an ensemble model, the correlation was 0.81. The ensemble model generalizes well in the validation studies across ancestries, despite differences in the measurements of NMR between studies, with correlations of: 0.52 for African ancestry, 0.61 for Asian ancestry, and 0.46 for European ancestry. The most influential predictors of NMR identified in more than two models were rs56113850, rs11878604, and 21 other genetic variants near CYP2A6 as well as age and ancestry.

conclusionsWe have developed an ensemble of seven models for predicting the NMR across ancestries from genotypes and age, gender and BMI. These models were validated using three datasets and associate with nicotine dosages. The knowledge of how an individual metabolizes nicotine could be used to help select the optimal path to reducing or quitting tobacco use, as well as, evaluating risks of tobacco use.

Indexed as

CotinineNicotineGenome-Wide Association StudyGenotypeHumansSmokingCotinineNicotineMachine learningNicotine biomarkersNicotine metabolismPolygenic risk scoreSmoking cessationStatistical learning

Identifiers

PMID36131240
PMCPMC9490935
OpenAlexW4296711667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.